FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023252309> ?p ?o ?g. }

• W2023252309 endingPage "1688" @default.
• W2023252309 startingPage "1680" @default.
• W2023252309 abstract "Background —The glycoprotein (GP) IIb/IIIa receptor antagonist abciximab is approved for use in high-risk percutaneous coronary interventions. The purpose of the present study was to establish the pharmacodynamic profile and platelet-bound life span of abciximab. Methods and Results —The pharmacodynamics of abciximab (inhibition of ex vivo platelet aggregation and GP IIb/IIIa receptor blockade) were measured in 41 individuals who were randomized to receive a 0.25-mg/kg bolus and a 12-hour infusion of either 10 μg/min (EPIC regimen) or 0.125 μg · kg −1 · min −1 (EPILOG regimen) of the antiplatelet agent. At extended times, the amount and distribution of platelet-bound abciximab were monitored by flow cytometry. The EPIC and EPILOG infusion regimens exhibited equivalent blockade of both GP IIb/IIIa receptors and platelet aggregation throughout the duration of abciximab treatment. Flow cytometry revealed a single, highly fluorescent platelet population during treatment, consistent with complete saturation and homogeneous distribution of abciximab on circulating platelets. For 15 days after treatment, the fluorescence histograms remained unimodal with gradually diminishing fluorescence intensity, indicating decreasing levels of platelet-bound abciximab. At 8 and 15 days, which exceeds the normal circulating life span of platelets, median relative fluorescence intensity corresponded to 29 100 (29% GP IIb/IIIa receptor blockade) and 13 300 (13% GP IIb/IIIa receptor blockade) abciximab molecules bound per platelet, respectively. Conclusions —These results are consistent with continuous reequilibration of abciximab among circulating platelets and may explain the gradual recovery of platelet function and long-term prevention of ischemic complications by abciximab after coronary intervention." @default.
• W2023252309 created "2016-06-24" @default.
• W2023252309 creator A5012183475 @default.
• W2023252309 creator A5013675555 @default.
• W2023252309 creator A5034778550 @default.
• W2023252309 creator A5039372316 @default.
• W2023252309 creator A5067335761 @default.
• W2023252309 creator A5072855474 @default.
• W2023252309 date "1998-05-05" @default.
• W2023252309 modified "2023-09-25" @default.
• W2023252309 title "Pharmacodynamic Profile of Short-term Abciximab Treatment Demonstrates Prolonged Platelet Inhibition With Gradual Recovery From GP IIb/IIIa Receptor Blockade" @default.
• W2023252309 cites W1602182436 @default.
• W2023252309 cites W1976753645 @default.
• W2023252309 cites W1982284371 @default.
• W2023252309 cites W1995552818 @default.
• W2023252309 cites W1997521359 @default.
• W2023252309 cites W2002060126 @default.
• W2023252309 cites W2053917461 @default.
• W2023252309 cites W2058198964 @default.
• W2023252309 cites W2063656702 @default.
• W2023252309 cites W2074030620 @default.
• W2023252309 cites W2082306741 @default.
• W2023252309 cites W2104950981 @default.
• W2023252309 cites W2112799238 @default.
• W2023252309 cites W2139755089 @default.
• W2023252309 cites W2148129851 @default.
• W2023252309 cites W2159642184 @default.
• W2023252309 cites W2163361020 @default.
• W2023252309 cites W2299926357 @default.
• W2023252309 cites W2395313915 @default.
• W2023252309 cites W3022148767 @default.
• W2023252309 cites W39893895 @default.
• W2023252309 cites W4211222686 @default.
• W2023252309 doi "https://doi.org/10.1161/01.cir.97.17.1680" @default.
• W2023252309 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9591761" @default.
• W2023252309 hasPublicationYear "1998" @default.
• W2023252309 type Work @default.
• W2023252309 sameAs 2023252309 @default.
• W2023252309 citedByCount "265" @default.
• W2023252309 countsByYear W20232523092012 @default.
• W2023252309 countsByYear W20232523092013 @default.
• W2023252309 countsByYear W20232523092014 @default.
• W2023252309 countsByYear W20232523092015 @default.
• W2023252309 countsByYear W20232523092016 @default.
• W2023252309 countsByYear W20232523092017 @default.
• W2023252309 countsByYear W20232523092018 @default.
• W2023252309 countsByYear W20232523092019 @default.
• W2023252309 countsByYear W20232523092020 @default.
• W2023252309 countsByYear W20232523092021 @default.
• W2023252309 countsByYear W20232523092022 @default.
• W2023252309 countsByYear W20232523092023 @default.
• W2023252309 crossrefType "journal-article" @default.
• W2023252309 hasAuthorship W2023252309A5012183475 @default.
• W2023252309 hasAuthorship W2023252309A5013675555 @default.
• W2023252309 hasAuthorship W2023252309A5034778550 @default.
• W2023252309 hasAuthorship W2023252309A5039372316 @default.
• W2023252309 hasAuthorship W2023252309A5067335761 @default.
• W2023252309 hasAuthorship W2023252309A5072855474 @default.
• W2023252309 hasBestOaLocation W20232523091 @default.
• W2023252309 hasConcept C111113717 @default.
• W2023252309 hasConcept C112705442 @default.
• W2023252309 hasConcept C126322002 @default.
• W2023252309 hasConcept C170493617 @default.
• W2023252309 hasConcept C2777871224 @default.
• W2023252309 hasConcept C2778468042 @default.
• W2023252309 hasConcept C2780400711 @default.
• W2023252309 hasConcept C2908647359 @default.
• W2023252309 hasConcept C2910542480 @default.
• W2023252309 hasConcept C3018697912 @default.
• W2023252309 hasConcept C500558357 @default.
• W2023252309 hasConcept C71924100 @default.
• W2023252309 hasConcept C89560881 @default.
• W2023252309 hasConcept C98274493 @default.
• W2023252309 hasConcept C99454951 @default.
• W2023252309 hasConceptScore W2023252309C111113717 @default.
• W2023252309 hasConceptScore W2023252309C112705442 @default.
• W2023252309 hasConceptScore W2023252309C126322002 @default.
• W2023252309 hasConceptScore W2023252309C170493617 @default.
• W2023252309 hasConceptScore W2023252309C2777871224 @default.
• W2023252309 hasConceptScore W2023252309C2778468042 @default.
• W2023252309 hasConceptScore W2023252309C2780400711 @default.
• W2023252309 hasConceptScore W2023252309C2908647359 @default.
• W2023252309 hasConceptScore W2023252309C2910542480 @default.
• W2023252309 hasConceptScore W2023252309C3018697912 @default.
• W2023252309 hasConceptScore W2023252309C500558357 @default.
• W2023252309 hasConceptScore W2023252309C71924100 @default.
• W2023252309 hasConceptScore W2023252309C89560881 @default.
• W2023252309 hasConceptScore W2023252309C98274493 @default.
• W2023252309 hasConceptScore W2023252309C99454951 @default.
• W2023252309 hasIssue "17" @default.
• W2023252309 hasLocation W20232523091 @default.
• W2023252309 hasLocation W20232523092 @default.
• W2023252309 hasOpenAccess W2023252309 @default.
• W2023252309 hasPrimaryLocation W20232523091 @default.
• W2023252309 hasRelatedWork W2021145671 @default.
• W2023252309 hasRelatedWork W2032341728 @default.
• W2023252309 hasRelatedWork W2033476357 @default.
• W2023252309 hasRelatedWork W2077772721 @default.

• next